Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120691 · ClinicalTrials.gov registry record · Phase 3
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,224
- Enrollment target
NCT01120691 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,224 participants.
The verdict
NCT01120691, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,224 participants
- Enrollment target
Study Summary
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
Interventions
- DRUG tiotropium
- DRUG NVA237
- DRUG QVA149
- DRUG Salbutamol/albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,224 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120691
The ClinicalTrials.gov registry entry for NCT01120691 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which tiotropium is the first listed.
NCT01120691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120691 about?
NCT01120691 is a clinical study titled "Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations". This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
What is the current status of trial NCT01120691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,224 participants. The study started on 2010-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01120691?
The interventions under investigation include: tiotropium (DRUG), NVA237 (DRUG), QVA149 (DRUG), Salbutamol/albuterol (DRUG).
Who is sponsoring clinical trial NCT01120691?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.